First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort

被引：0
|
作者：
Yu, Jinming
Sun, Yuping
Dang, Qi
Zhang, Yan
Du, Jintong
Wei, Yonggang
Ye, Fei
Liu, Rui
Zhao, Qi
Li, Zhiyong
机构：
[1] Shandong Univ, Shandong Canc Hosp, Jinan, Peoples R China
[2] Shandong Canc Hosp, Jinan, Peoples R China
[3] Shandong Canc Hosp, Jinan, Shandong, Peoples R China
[4] Shandong First Med Univ, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[5] Shandong Acad Med Sci, Jinan, Shandong, Peoples R China
[6] Chengdu Baiyu Pharmaceut Co Ltd, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15132
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety, tolerability, and pharmacokinetics of idebenone in a dose-escalation trial in patients with Friedreich's ataxia.
    Di Prospero, NA
    Sumner, C
    Atkinson, A
    Fischbeck, K
    Taylor, JP
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P68 - P68
  • [22] Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
    Xu, Hongrong
    Sheng, Lei
    Chen, Weili
    Yuan, Fei
    Yang, Mengjie
    Li, Hui
    Li, Xuening
    Choi, John
    Zhao, Guiyu
    Hu, Tianxin
    Li, Yongguo
    Zhang, Yi
    Chen, Li
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1619 - 1626
  • [23] A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
    Ahmadi, Ali R.
    Atiee, George
    Chapman, Bart
    Reynolds, Laurie
    Sun, John
    Cameron, Andrew M.
    Wesson, Russell N.
    Burdick, James F.
    Sun, Zhaoli
    CELL REPORTS MEDICINE, 2023, 4 (09)
  • [24] A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors
    Ma, Fei
    Xu, Nong
    Tang, Huoling
    Zhou, Yuhong
    Wei, Ziping
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects
    Masaomi Takizawa
    Dirk Cerneus
    Ingrid Michon
    Sanne Rijnders
    Desiree van der Heide
    John Meijer
    Matthias Stoelzel
    Yuichiro Sato
    Advances in Therapy, 2020, 37 : 3878 - 3900
  • [26] Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial
    Li, Cuiyun
    Wu, Min
    Zhang, Hong
    Mai, Jiajia
    Yang, Lizhi
    Ding, Yanhua
    Niu, Junqi
    Mao, John
    Wu, Wenqiang
    Zhang, Dong
    Tang, Yanan
    Yan, Wenhao
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (10)
  • [27] The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects
    Takizawa, Masaomi
    Cerneus, Dirk
    Michon, Ingrid
    Rijnders, Sanne
    van der Heide, Desiree
    Meijer, John
    Stoelzel, Matthias
    Sato, Yuichiro
    ADVANCES IN THERAPY, 2020, 37 (09) : 3878 - 3900
  • [28] Autologous Macrophage Therapy for Liver Cirrhosis (MATCH): A First-in-Human, Phase 1, Single-Arm, Dose-Escalation Trial
    Moroni, Francesca
    Dwyer, Benjamin
    Glover, Alison
    Graham, Catriona
    Mcgowan, Neil
    Fraser, Alasdair
    Campbell, John
    Atkinson, Anne
    Mitchell, Donna
    Pass, Chloe
    Bailey, Laura
    Turner, Mark
    Hayes, Peter C.
    Fallowfield, Jonathan Andrew
    Forbes, Stuart J.
    HEPATOLOGY, 2018, 68 : 1127A - 1128A
  • [29] First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors
    Eskens, F.
    Opdam, F.
    Gort, E.
    Gelderblom, H.
    Prestegarden, L.
    Pico-Navarro, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S758 - S758
  • [30] Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial
    Eelke M. Bos
    Elena Binda
    Iris S.C. Verploegh
    Eva Wembacher
    Daphna Hoefnagel
    Rutger K. Balvers
    Anne L. Korporaal
    Andrea Conidi
    Esther A. H. Warnert
    Nadia Trivieri
    Alberto Visioli
    Paola Zaccarini
    Laura Caiola
    Rogier van Wijck
    Peter van der Spek
    Danny Huylebroeck
    Sieger Leenstra
    Martine L.M. Lamfers
    Zvi Ram
    Manfred Westphal
    David Noske
    Federico Legnani
    Francesco DiMeco
    Angelo Luigi Vescovi
    Clemens M.F. Dirven
    Molecular Cancer, 22
12345